Tag Archives: BPMC

Tuesday’s Midday Stock Update: Rite Aid (RAD), Teva Pharmaceutical Industries (TEVA), Bluebird Bio (BLUE), Blueprint Medicines (BPMC), SunPower (SPWR)

So far Tuesday, January 14, NASDAQ is up 0.1% and the S&P is up 0.51%. Here are this morning’s most active stocks: Rite Aid (RAD – Research Report), Teva Pharmaceutical Industries (TEVA – Research Report), Bluebird Bio (BLUE – Research

Monday’s Highlights at Noon: SunPower (SPWR), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), uniQure (QURE), Ballard Power Systems (BLDP)

So far Monday, January 13, NASDAQ is up 2.43% and the S&P is up 1.12%. Here are this morning’s most active stocks: SunPower (SPWR – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report), Blueprint Medicines (BPMC – Research Report), uniQure

Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (NASDAQ: BPMC), SCYNEXIS (NASDAQ: SCYX) and Kindred Biosciences (NASDAQ: KIN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC – Research Report), SCYNEXIS (SCYX – Research Report) and Kindred Biosciences (KIN – Research Report) with bullish sentiments. Blueprint

Monday’s Midday Stock Update: Karyopharm Therapeutics (KPTI), Peabody Energy Comm (BTU), Arrowhead Research (ARWR), Blueprint Medicines (BPMC), Aerie Pharma (AERI)

So far Monday, December 2, NASDAQ is down -4.72% and the S&P is down -2.6%. Here are this morning’s most active stocks: Karyopharm Therapeutics (KPTI – Research Report), Peabody Energy Comm (BTU – Research Report), Arrowhead Research (ARWR – Research

Friday’s Midday Movers: Clovis Oncology (CLVS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Arrowhead Research (ARWR), United States Steel (X)

So far Friday, November 29, NASDAQ is up 0.26% and the S&P is down -0.36%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Clovis Oncology (CLVS – Research Report), TG Therapeutics (TGTX –

Blueprint Medicines (BPMC) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $100.00. The company’s shares closed last Monday at $74.10. According to TipRanks.com, Fein is a 4-star analyst